CHARDAN HEALTHCARE CONFERENCE – 10 YEARS OF DISRUPTIVE INNOVATION - PALVELLA THERAPEUTICS INC

Financial Performance:

• Raised $230 million earlier this year, providing sufficient funding to sustain development programs for the next couple of years.
• Projected peak sales of $1 billion to $3 billion combined for the lead asset across two major indications (Microcystic Lymphatic Malformations and Cutaneous Venous Malformations).
• Pricing strategy targeted at $100,000 to $200,000 per patient annually.
• No specific revenue, GAAP earnings, or cash flow figures provided for the current quarter as the company remains in clinical development.

Guidance and Future Outlook:

• Rolling New Drug Application (NDA) submitted for Cuturin Rapamycin in microcystic lymphatic malformations (MLM) in late August.
• Expected FDA PDUFA date in the first half of next year, likely around late April.
• Anticipates transitioning to a commercial entity immediately following FDA approval.
• Pipeline expansion plan: By year-end, aims to have three drug products treating six distinct diseases.
• Phase II trial for Cuturin Pitavastatin in Disseminated Superficial Actinic Porokeratosis (DSAP) planned to initiate later this quarter.
• Two additional disease indications and one new drug product will be announced before year-end.

Business Segments and Product Lines:

• Lead Asset (Cuturin Rapamycin):
  • MLM: First indication; phase III data announced; NDA pending FDA decision. Market size estimated at 30,000 U.S. patients.
  • Cutaneous Venous Malformations (CVM): Second indication; phase II data positive; addresses functional impairment in >75,000 patients. Estimated as the larger revenue driver ($2B vs $1B peak sales).
  • Clinically Significant Angiokeratomas: Phase II trial currently ongoing.
  • Fourth Indication: To be announced by year-end.
• Second Program (Cuturin Pitavastatin):
  • Focusing on DSAP; phase II trial starting later this quarter.
• Platform Technology (Q-Torium):
  • Anhydrous gel platform allowing high/tunable drug loading; proprietary IP generated for each new molecule pairing.
  • Enables manufacturing efficiencies and rapid progression of new molecules into clinical trials.

Market and Competitive Landscape:

• Targets rare, serious, chronic genetic diseases with no approved treatments.
• MLM Market: 30,000 U.S. patients; current treatments (surgery, sclerotherapy) offer temporary/ineffective results; off-label rapamycin usage exists but is not standardized.
• CVM Market: >75,000 patients; symptoms include bleeding, thrombosis, pain, and significant functional disability; current landscape lacks effective therapies for cutaneous manifestations.
• Payer Engagement: Positive discussions with payers regarding pricing and market access.
• Competitive Advantage: First-in-class potential for all targeted indications; proprietary formulation technology differentiates from compounded rapamycin.

Risks and Challenges:

• FDA Regulatory Risk: Did not receive Breakthrough Therapy designation on first attempt for CVM; pivotal trial design to be finalized via End-of-Phase II meeting, with potential for re-application later.
• Development Risk: Reliance on successful trial designs and patient recruitment for Phase II and III programs across multiple rare diseases.
• Commercial Execution: Success dependent on building a functional commercial team and securing market adoption for high-cost therapies.

Management Commentary and Tone:

• Tone is confident and transition-focused, shifting from clinical development to commercialization.
• Management emphasizes speed to market ("get drug to patients as fast as possible") over regulatory designations.
• Highlights the strategic shift from a single-disease focus to a multi-disease portfolio of three drugs.
• Expresses optimism regarding the NDA review timeline and the long-term value of the Q-Torium platform.

Analyst Questions and Answers:

• Q: Market size and pricing for MLM? A: 30,000 U.S. patients; pricing $100k–$200k/year; peak sales ~$1B.
• Q: Differentiation of Cuturin from compounded rapamycin? A: Proprietary anhydrous gel (Q-Torium) with tunable drug loading, validated through 80 prototypes, creating new IP.
• Q: Details on CVM and functional impairment? A: >75,000 patients; primary symptom is functional disability (e.g., inability to bend joints, wear clothes); treats cutaneous, not internal, manifestations.
• Q: Status of Breakthrough Therapy designation? A: Not obtained initially; focus now on efficient Phase III trial design with FDA; re-application possible if deemed appropriate after End-of-Phase II meeting.
• Q: Future pipeline updates? A: Two new programs (one existing drug new indication, one new drug) to be announced by year-end; total of six diseases across three drugs by year-end.

Other Key Points:

• Commercial team fully assembled: Ashley Klein (CCO, formerly Dompe), Kent Taylor (Head of Sales), Jen McDonough (Head of Market Access), Vimal Patel (Marketing), and Peter Finlayson (Medical Affairs).
• Current activities focus on disease education and seeding the market among prescribers.
• Platform IP strategy: Every new molecule paired with Q-Torium generates new intellectual property.